Hyperion DeFi (NASDAQ:HYPD) Trading Down 8.5% – What’s Next?

Hyperion DeFi, Inc. (NASDAQ:HYPD)’s stock price traded down 8.5% on Tuesday . The company traded as low as $3.72 and last traded at $3.79. 402,642 shares changed hands during trading, a decline of 17% from the average session volume of 483,909 shares. The stock had previously closed at $4.14.

Wall Street Analyst Weigh In

HYPD has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Zacks Research raised Hyperion DeFi to a “hold” rating in a report on Monday, December 29th. Cantor Fitzgerald assumed coverage on Hyperion DeFi in a research report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price objective for the company. Finally, Chardan Capital set a $7.75 target price on Hyperion DeFi and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Hyperion DeFi has a consensus rating of “Hold” and a consensus target price of $4.58.

Hyperion DeFi Trading Down 8.5%

The firm has a 50-day moving average of $3.58 and a 200 day moving average of $5.89. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $30.96 million, a price-to-earnings ratio of -0.94 and a beta of 2.69.

Insider Activity at Hyperion DeFi

In other news, Director Michael S. Geltzeiler purchased 30,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was purchased at an average cost of $3.01 per share, with a total value of $90,300.00. Following the purchase, the director owned 88,015 shares in the company, valued at $264,925.15. This trade represents a 51.71% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO David R. Knox acquired 27,950 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was purchased at an average price of $3.59 per share, with a total value of $100,340.50. Following the acquisition, the chief financial officer owned 327,950 shares of the company’s stock, valued at approximately $1,177,340.50. This trade represents a 9.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 189,204 shares of company stock worth $611,467. 10.86% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hyperion DeFi

Several hedge funds and other institutional investors have recently bought and sold shares of HYPD. Sanctuary Advisors LLC bought a new stake in shares of Hyperion DeFi during the 4th quarter worth $38,000. Nations Financial Group Inc. IA ADV acquired a new position in shares of Hyperion DeFi in the 4th quarter valued at $40,000. Price T Rowe Associates Inc. MD purchased a new position in Hyperion DeFi in the 4th quarter worth about $73,000. Formidable Asset Management LLC acquired a new stake in Hyperion DeFi during the 4th quarter worth about $83,000. Finally, State Street Corp purchased a new stake in Hyperion DeFi during the fourth quarter valued at about $92,000. 25.84% of the stock is currently owned by institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.